am 251 has been researched along with Xerostomia in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Xerostomia: Decreased salivary flow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prestifilippo, JP | 1 |
| Medina, VA | 1 |
| Mohn, CE | 1 |
| Rodriguez, PA | 1 |
| Elverdin, JC | 1 |
| Fernandez-Solari, J | 1 |
1 other study available for am 251 and Xerostomia
| Article | Year |
|---|---|
Endocannabinoids mediate hyposalivation induced by inflammogens in the submandibular glands and hypothalamus.
Topics: Analysis of Variance; Animals; Cannabinoid Receptor Agonists; Dinoprostone; Endocannabinoids; Hypoth | 2013 |